Cargando…

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendix, Mia, Dige, Anders, Jørgensen, Søren Peter, Dahlerup, Jens Frederik, Bibby, Bo Martin, Deleuran, Bent, Agnholt, Jørgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759913/
https://www.ncbi.nlm.nih.gov/pubmed/33266022
http://dx.doi.org/10.3390/nu12123699
_version_ 1783627209119891456
author Bendix, Mia
Dige, Anders
Jørgensen, Søren Peter
Dahlerup, Jens Frederik
Bibby, Bo Martin
Deleuran, Bent
Agnholt, Jørgen
author_facet Bendix, Mia
Dige, Anders
Jørgensen, Søren Peter
Dahlerup, Jens Frederik
Bibby, Bo Martin
Deleuran, Bent
Agnholt, Jørgen
author_sort Bendix, Mia
collection PubMed
description Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34.
format Online
Article
Text
id pubmed-7759913
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77599132020-12-26 Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab Bendix, Mia Dige, Anders Jørgensen, Søren Peter Dahlerup, Jens Frederik Bibby, Bo Martin Deleuran, Bent Agnholt, Jørgen Nutrients Article Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34. MDPI 2020-11-30 /pmc/articles/PMC7759913/ /pubmed/33266022 http://dx.doi.org/10.3390/nu12123699 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bendix, Mia
Dige, Anders
Jørgensen, Søren Peter
Dahlerup, Jens Frederik
Bibby, Bo Martin
Deleuran, Bent
Agnholt, Jørgen
Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
title Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
title_full Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
title_fullStr Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
title_full_unstemmed Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
title_short Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
title_sort decrease in mucosal il17a, ifnγ and il10 expressions in active crohn’s disease patients treated with high-dose vitamin d alone or combined with infliximab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759913/
https://www.ncbi.nlm.nih.gov/pubmed/33266022
http://dx.doi.org/10.3390/nu12123699
work_keys_str_mv AT bendixmia decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab
AT digeanders decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab
AT jørgensensørenpeter decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab
AT dahlerupjensfrederik decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab
AT bibbybomartin decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab
AT deleuranbent decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab
AT agnholtjørgen decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab